| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, Fmoc-N-Me-D-Ala-OH has no specific biological target. Its role is to provide N-methyl-D-alanine residues in peptide chains. The Fmoc protecting group enables standard Fmoc solid-phase peptide synthesis (SPPS) workflows, allowing for the controlled assembly of peptide chains. The N-methyl group introduces a secondary amide bond when incorporated into peptides, which can significantly alter peptide conformation, enhance metabolic stability, and modulate biological activity. The D-configuration of the alanine residue introduces stereochemical diversity compared to L-alanine, which can be valuable for structure-activity relationship studies. The compound does not interact with enzymes or receptors in pharmacological assays. Its "target" is the peptide coupling reaction, where it acts as a protected amino acid donor.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Fmoc-N-Me-D-Ala-OH is measured by coupling efficiency in solid-phase peptide synthesis (SPPS). Typically, it is coupled to resin-bound amine using standard Fmoc-SPPS conditions: deprotection of the resin-bound Fmoc group with 20% piperidine in DMF, followed by coupling with Fmoc-N-Me-D-Ala-OH (typically 3-5 equivalents) using coupling reagents such as HATU, HBTU, or DIC with HOBt, and DIEA as base. The coupling reaction is typically performed at room temperature for 1-4 hours. Coupling efficiency is monitored by the Kaiser test or by quantitative HPLC. Purity is typically ≥98.0% (TLC) or ≥99.5% (Chiral HPLC). No inherent biological activity is observed as the compound is a protected amino acid derivative. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. |
| ln Vivo |
In vivo activity is not applicable for Fmoc-N-Me-D-Ala-OH. The compound is not used in animals and is a research chemical for laboratory synthesis only. It is not intended for therapeutic or diagnostic purposes.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Fmoc-N-Me-D-Ala-OH involves standard Fmoc solid-phase peptide synthesis procedures. Standard SPPS cycle: deprotect Fmoc with 20% piperidine in DMF (typically 2 × 5-10 minutes), wash with DMF, couple Fmoc-N-Me-D-Ala-OH (3 equiv.) with HATU (2.9 equiv.) and DIEA (6 equiv.) for 1-2 hours, wash, repeat. After complete assembly of the peptide sequence, the peptide is cleaved from the resin and deprotected using a cleavage cocktail containing TFA, TIS, and water (typically 95:2.5:2.5) for 2-4 hours. The crude peptide is precipitated with cold ether, and the product is analyzed by HPLC-MS. The compound's IUPAC name is (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid.
|
| Cell Assay |
In vitro cell-based experimental workflows are not performed on this intermediate. The final deprotected peptides may be tested in cell-based assays, but the protected compound itself is not used.
|
| Animal Protocol |
In vivo animal experiments are not applicable for Fmoc-N-Me-D-Ala-OH. The compound is stored as a powder at -20°C or 4°C.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Fmoc-N-Me-D-Ala-OH have not been characterized. The compound is not a drug. No ADME data are available. The compound is stable under recommended storage conditions: powder at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent at -80°C for up to 1 month.
|
| Toxicity/Toxicokinetics |
The toxicological data for Fmoc-N-Me-D-Ala-OH are not well-documented. Standard laboratory safety practices should be followed. The compound is intended for research use only and is not for human or veterinary use.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1061.
|
| Additional Infomation |
Fmoc-N-Me-D-Ala-OH is a specialized building block for Fmoc-based solid-phase peptide synthesis. The N-methylation introduces a secondary amide bond when incorporated into peptides, which can significantly alter peptide conformation and enhance metabolic stability. The compound is an alanine derivative and is available with high purity (≥98.0% TLC or ≥99.5% Chiral HPLC). It is not a drug and has no clinical trials or approvals. The compound is for research use only. It is soluble in DMSO at 90 mg/mL.
|
| Molecular Formula |
C19H19NO4
|
|---|---|
| Molecular Weight |
325.36
|
| Exact Mass |
325.131
|
| CAS # |
138774-92-2
|
| PubChem CID |
688633
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
514.9±29.0 °C at 760 mmHg
|
| Flash Point |
265.2±24.3 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
4.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](C(=O)O)N(C)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
JOFHWKQIQLPZTC-GFCCVEGCSA-N
|
| InChi Code |
InChI=1S/C19H19NO4/c1-12(18(21)22)20(2)19(23)24-11-17-15-9-5-3-7-13(15)14-8-4-6-10-16(14)17/h3-10,12,17H,11H2,1-2H3,(H,21,22)/t12-/m1/s1
|
| Chemical Name |
(2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (307.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0735 mL | 15.3676 mL | 30.7352 mL | |
| 5 mM | 0.6147 mL | 3.0735 mL | 6.1470 mL | |
| 10 mM | 0.3074 mL | 1.5368 mL | 3.0735 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
